DINA 006
Alternative Names: DINA-006Latest Information Update: 03 Jan 2023
At a glance
- Originator DiNAQOR AG
- Class Cardiovascular therapies; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Dilated cardiomyopathy
Most Recent Events
- 02 Jan 2023 Preclinical trials in Dilated cardiomyopathy in Switzerland (Parenteral) as of January 2023 (DiNAQOR pipeline, January 2023)
- 10 Feb 2022 DiNAQOR AG enters a collaboration with the University Medical Centre Hamburg Eppendorf for testing gene therapies, prior to February 2022
- 04 Feb 2022 Early research in Dilated cardiomyopathy in Switzerland (Parenteral) (DiNAQOR AG pipeline, February 2022)